BR112014024736A2 - antagonista receptor de h3 para uso no tratamento de doença de alzheimer - Google Patents

antagonista receptor de h3 para uso no tratamento de doença de alzheimer

Info

Publication number
BR112014024736A2
BR112014024736A2 BR112014024736A BR112014024736A BR112014024736A2 BR 112014024736 A2 BR112014024736 A2 BR 112014024736A2 BR 112014024736 A BR112014024736 A BR 112014024736A BR 112014024736 A BR112014024736 A BR 112014024736A BR 112014024736 A2 BR112014024736 A2 BR 112014024736A2
Authority
BR
Brazil
Prior art keywords
alzheimer
disease
treatment
receptor antagonist
tauopathies
Prior art date
Application number
BR112014024736A
Other languages
English (en)
Inventor
Menager Jean
Lopez Grancha Mathilde
Schussler Nathalie
Barneoud Pascal
Delay-Goyet Philippe
Rooney Thomas
Blanchard-Bregeon Véronique
Mary Véronique
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014024736A2 publication Critical patent/BR112014024736A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "antagonista receptor de h3 para uso no tratamento de doença de alzheimer". a presente invenção refere-se aos métodos de usar 2-(ciclo-hexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetra-hidroisoquinolina-7-sulfonamida em uma terapia de modificação da doença de alzheimer, outras tauopatias e doenças neurodegenerativas relacionadas.
BR112014024736A 2012-04-06 2013-04-05 antagonista receptor de h3 para uso no tratamento de doença de alzheimer BR112014024736A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305415.7A EP2647377A1 (en) 2012-04-06 2012-04-06 Use of an h3 receptor antagonist for the treatment of alzheimer's disease
US201361792635P 2013-03-15 2013-03-15
PCT/EP2013/057241 WO2013150150A1 (en) 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112014024736A2 true BR112014024736A2 (pt) 2017-07-11

Family

ID=46001073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024736A BR112014024736A2 (pt) 2012-04-06 2013-04-05 antagonista receptor de h3 para uso no tratamento de doença de alzheimer

Country Status (17)

Country Link
US (2) US20150031893A1 (pt)
EP (2) EP2647377A1 (pt)
JP (1) JP6143842B2 (pt)
KR (1) KR20150000490A (pt)
CN (1) CN104363911A (pt)
AR (1) AR090605A1 (pt)
AU (1) AU2013244928B2 (pt)
BR (1) BR112014024736A2 (pt)
CA (1) CA2868481A1 (pt)
ES (1) ES2618924T3 (pt)
MX (1) MX354020B (pt)
PL (1) PL2833887T3 (pt)
RU (1) RU2014144615A (pt)
SG (2) SG10201801200PA (pt)
TW (1) TW201402119A (pt)
UY (1) UY34734A (pt)
WO (1) WO2013150150A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN114053289B (zh) * 2020-08-06 2023-06-27 北京箭牧科技有限公司 瑞德西韦在制备预防和治疗神经系统退行性疾病药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003274053A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
BR0317483A (pt) 2002-12-20 2005-11-16 Glaxo Group Ltd Derivados de benzodiazepina para o tratamento de desordens neurológicas
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
SI1615909T1 (sl) 2003-04-23 2008-12-31 Glaxo Group Ltd Derivati piperazina in njihova uporaba za zdravljenje nevroloĺ kih in psihiatriäśnih bolezni
WO2005014571A1 (en) 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1756094A1 (en) 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
JP2008516922A (ja) 2004-10-15 2008-05-22 グラクソ グループ リミテッド ヒスタミン受容体リガンドとしてのピロリジン誘導体
EP1833796A1 (en) 2004-12-07 2007-09-19 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
EA200701984A1 (ru) 2005-03-14 2008-02-28 Глэксо Груп Лимитед Конденсированные тиазольные производные, обладающие сродством к гистаминовому h3 рецептору
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PT2040755E (pt) 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
CL2008000597A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
CL2008002622A1 (es) 2007-09-06 2009-11-27 Glaxo Group Ltd 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2328587A1 (en) 2008-08-29 2011-06-08 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{ [4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine or a salt thereof
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CA2766154C (en) 2009-06-26 2015-04-07 Beverly C. Langevin Novel fumarate salts of a histamine h3 receptor antagonist
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
FR2976286B1 (fr) 2011-06-08 2013-05-24 Servier Lab 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Also Published As

Publication number Publication date
ES2618924T3 (es) 2017-06-22
CA2868481A1 (en) 2013-10-10
MX354020B (es) 2018-02-08
PL2833887T3 (pl) 2017-06-30
AU2013244928A1 (en) 2014-10-30
EP2647377A1 (en) 2013-10-09
WO2013150150A1 (en) 2013-10-10
JP2015516963A (ja) 2015-06-18
UY34734A (es) 2013-11-29
SG10201801200PA (en) 2018-04-27
CN104363911A (zh) 2015-02-18
AU2013244928B2 (en) 2017-08-10
US20150031893A1 (en) 2015-01-29
EP2833887B1 (en) 2016-12-28
JP6143842B2 (ja) 2017-06-07
AR090605A1 (es) 2014-11-26
US9789102B2 (en) 2017-10-17
MX2014011992A (es) 2015-05-08
EP2833887A1 (en) 2015-02-11
TW201402119A (zh) 2014-01-16
RU2014144615A (ru) 2016-05-27
SG11201406093VA (en) 2014-10-30
KR20150000490A (ko) 2015-01-02
US20160101099A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
BR112015026325A2 (pt) dosagem oral de compostos glp-1
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA027953B9 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
SI2771329T1 (sl) Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni
IN2012DN05186A (pt)
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
UA117154C2 (uk) Антагоністи s1p3
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.